According to a market report by Lucintel, the future of the global cancer cachexia market looks promising with opportunities in the progestogen, corticosteroid, and combination therapy markets. The global cancer cachexia market is expected to reach an estimated $3.0 billion by 2030 with a CAGR of 4.0% from 2024 to 2030. The major drivers for this market are growing prevalence of cancer cachexia, increasing old age population, and evolving treatment landscape.
A more than 150 – page report is developed to understand Trends, opportunity and forecast in cancer cachexia market to 2030 by mode of action (appetite stimulators, weight loss stabilizers, and others), drugs (progestogens, corticosteroids, combination therapies, and others), distribution channel (hospital stores, retail pharmacy, and online pharmacy), and region (North America, Europe, Asia Pacific, and the Rest of the World).
In this market, appetite stimulator and weight loss stabilizer are the major segments of cancer cachexia market by mode of action. Lucintel forecasts that appetite stimulator is expected to witness the higher growth over the forecast period due to rise in appetite stimulant research and development for cancer cachexia.
Within this market, progestogen will remain the largest segment due to its excellent efficacy in treating cancer cachexia and their affordable price.
Download sample by clicking on cancer cachexia market
North America will remain the largest region over the forecast period due to the presence of numerous drug makers, as well as the evolving paradigm of cancer care.
Aeterna Zentaris, Aphios, Bristol-Myers Squibb, Pfizer, Helsinn Group, Merck, Artelo Biosciences Inc., Ngm Biopharmaceuticals, Aveo Oncology, and Aavogen are the major suppliers in the cancer cachexia market.
This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or write us at [email protected]